Navigation Links
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Date:9/15/2009

e K group.

For a complete list of posters, please visit the Resources webpage on our Web site at www.optimerpharma.com

Fidaxomicin Clinical Study Design

629 adult subjects were enrolled in this multi-center, randomized, double-blind phase 3 clinical trial, which was the largest such trial for the treatment of CDI. Subjects with confirmed CDI received either 200 mg fidaxomicin dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

About Clostridium Difficile Infection

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food ... therapy for patients suffering from gallstones in whom ... disease or advanced age. ,, Chenodal prescriptions have ... Centric Health Resources ("Centric"), a specialty pharmacy company. ...
(Date:12/14/2009)... Dec. 14 Travelers of Interstate 70 west ... become a bit more colorful when 10 multicolored art ... is named going home , will eventually include ... a graduate student at Herron School of Art and ... Public Life. ,, Eli Lilly and Company (NYSE: ...
(Date:12/14/2009)... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... of directors with the addition of Lt. Gen. Ronald ... chairman of Martin, Blanck & Associates, a federal health ... his addition, the company board now has nine members. ... as a medical officer and battalion surgeon in Vietnam. ...
Breaking Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Oxygen Biotherapeutics, Inc. Expands Board of Directors 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 1Cantel Medical Corp to Hold Conference Call to Discuss Results for its First Quarter Ended October 31 2009 6687 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 1AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 6683 3
... FRANCISCO, Calif., Nov. 6 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... the,company,s novel oral Factor Xa inhibitor and ... presented at the American Heart Association,(AHA) Scientific ...
... Bavarian,Nordic has completed a clinical safety report from a ... that confirms the excellent,safety profile of IMVAMUNE(R). Within the ... be submitted to the FDA and this will trigger ... The clinical safety,report constitutes a major part of the ...
Other Medicine Technology:Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008 2Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R) 2
(Date:12/15/2009)... DALLAS Dec. 15, 2009 UT Southwestern ... account to date of the unique observable characteristics ... aging syndrome. , The findings, reported online and ... of Clinical Endocrinology and Metabolism, suggest that ... be lumped together with those diagnosed with two ...
(Date:12/14/2009)... ANN ARBOR, Mich., Dec. 14 ... and the Commonwealth of Kentucky are among the ... solution this fall to help their employees make ... Enrollment solution gives employees a personalized summary of ... cost of that care. With this personalized information, ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... gardening replaced tube watching , , MONDAY, Dec. 14 (HealthDay ... hours of television a week until he enrolled in ... time in half. , During his enforced period of ... not necessarily through strenuous exercise, although he did find ... time was spent reading and working on the computer, ...
(Date:12/14/2009)... Statement of Steve Pasierb, President ,, NEW ... of Michigan,s Monitoring the Future study (MTF) -- the ... 8th, 10th and 12th graders -- underscores that teens, ... continues to be a cause for concern, with an ... from friends and relatives. ,, Teen ...
Breaking Medicine News(10 mins):Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Cutting TV Time Burns More Calories 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3
... of ban on their export of seafood to Canada as ... the banned chemical Malachite green in the fish tissues.// ... follow strict stringent rules and should test all batches of ... Malachite green and its byproducts. Consumer Association of Canada feels ...
... a deadly potion was brought home in a very uncomfortable ... of the greatest footballers' died in London yesterday. // ... own liver failed in the aftermath of his boozing exploits. ... world over, mostly male, suffer from alcohol-related liver disease each ...
... Insulin like-Growth Factor (IGF-1) is required for both ... secretion of IGF is mediated by the pituitary ... and is associated with metabolic abnormalities including insulin ... drugs helps in production of IGF-1 in children’s ...
... view, of the ever-increasing threat about bird flu worldwide, there ... manufacture the drug.// Ranbaxy Laboratories has become the first Indian ... drug, Tamiflu. The drug is believed to get shipped to ... Roche would be invalid. ,We have sent small ...
... prices and breakdown of electricity supplies, upto 90,000 senior ... have warned.//,As the Meteorological Office has issued its second ... gas - essential to warm homes - while some ... winter. ,Charity organisations caring for the elderly warned ...
... ideal sleeping position for toddlers with a new study ... when they sleep on their backs rather than on ... likely to be experienced by children who have sleep ... ,The study observed nearly 60 ...
Other Medicine News:Health News:Harsh British Winter Could Kill Upto 90,000 Pensioners 2
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: